{"organizations": [], "uuid": "739afcacd12d9c00bdb6bfaaaf89e41a1879ff5e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/19/globe-newswire-michael-schmidt-to-join-guggenheim-securities-as-biotech-analyst.html", "country": "US", "domain_rank": 767, "title": "Michael Schmidt to Join Guggenheim Securities as Biotech Analyst", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.995, "site_type": "news", "published": "2018-03-19T19:00:00.000+02:00", "replies_count": 0, "uuid": "739afcacd12d9c00bdb6bfaaaf89e41a1879ff5e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/19/globe-newswire-michael-schmidt-to-join-guggenheim-securities-as-biotech-analyst.html", "ord_in_thread": 0, "title": "Michael Schmidt to Join Guggenheim Securities as Biotech Analyst", "locations": [], "entities": {"persons": [{"name": "michael schmidt", "sentiment": "negative"}, {"name": "schmidt", "sentiment": "none"}, {"name": "michael", "sentiment": "none"}, {"name": "leerink", "sentiment": "none"}, {"name": "stefano natella", "sentiment": "none"}], "locations": [{"name": "susquehanna", "sentiment": "none"}], "organizations": [{"name": "guggenheim securities", "sentiment": "negative"}, {"name": "leerink partners", "sentiment": "none"}, {"name": "equity research", "sentiment": "none"}, {"name": "harvard university", "sentiment": "none"}, {"name": "guggenheim partners", "sentiment": "none"}, {"name": "healthcare research", "sentiment": "none"}, {"name": "susquehanna international group", "sentiment": "none"}, {"name": "institutional investor all-america research survey", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Schmidt, Ph.D. will join the firm in June as a Senior Analyst and Senior Managing Director in a planned expansion of the firm’s Healthcare Research team. Dr. Schmidt will focus on the coverage of Biotech companies, working closely with our growing therapeutics team.\nDr. Schmidt will join Guggenheim from LEERINK Partners, where he has been an equity research analyst since 2009 and was named runner-up in the 2017 Institutional Investor All-America Research Survey in the Biotech/Mid- & Small-Cap category. Previous to joining LEERINK in 2009, he was a healthcare analyst and consultant for Susquehanna International Group’s private equity team. Dr. Schmidt was a research fellow at Harvard University previous to his work at Susquehanna.\n“We are excited to have Michael join our growing healthcare equity research team,” said Stefano Natella, Director of Equity Research. “He represents an important next step in our plan to invest substantially in our research capabilities, particularly in the healthcare sector. We look forward to his continued success at Guggenheim.”\nMichael Schmidt received his Ph.D. and M.Sc. from the University of Stuttgart in biochemistry and molecular genetics, respectively.\nAbout Guggenheim Securities\nGuggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at GSinfo@GuggenheimPartners.com or 212.518.9200.\nAbout Guggenheim Partners\nGuggenheim Partners is a global investment and advisory firm with more than $305 billion 1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs .\n1 Assets under management are as of 12.31.2017 and include consulting services for clients whose assets are valued at approximately $66bn.\nMedia Contact\nEllen Cunningham\nGuggenheim Partners\n212.518.9578\nEllen.N.Cunningham@GuggenheimPartners.com\nSource:Guggenheim Securities", "external_links": ["http://twitter.com/guggenheimptnrs", "https://www.globenewswire.com/Tracker?data=_v8ojkHHcZxYGxSFT4WcVNwXwlU6_o4ClT-U055wXCiivjS1l9p98jFdwwhQIyXJtnh2mBZfR0tKuPkKE3VjfXGqo2UQ3vnjTjzv7XEKv7I4Djgr9DuZ3MejXEJZSBqpzZpC9qAQsfVncwRwEsGHsA=="], "published": "2018-03-19T19:00:00.000+02:00", "crawled": "2018-03-19T21:32:20.055+02:00", "highlightTitle": ""}